RHONE-POULENC RORER COMMENTS ON RECENT INTEREST IN PROGRESS ON AIDS IMMUNOTHERAPEUTICS IN CLINICAL STUDIES
RHONE-POULENC RORER COMMENTS ON RECENT INTEREST IN PROGRESS
ON AIDS IMMUNOTHERAPEUTICS IN CLINICAL STUDIES
COLLEGEVILLE, Pa., Nov. 13 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) commented today on the recent interest in progress on AIDS immunotherapeutics in clinical studies and on yesterday's FDA Advisory Committee meeting discussing surrogate end-points in AIDS therapies.
In conjunction with Immune Response Corporation, RPR is conducting Phase II/III clinical trials on an AIDS therapeutic vaccine. These double-blind, placebo-controlled studies began in September 1990 and are scheduled to conclude in late 1992. To date, these and other studies indicate that the product appears safe and well tolerated.
As RPR has previously stated, until these studies are completed, the company will not have any clear indication of whether or not the product appears to be effective in preventing the transition to AIDS in seropositive patients. The studies are designed to capture changes in viral burden, T-cell counts and clinical end points. Consistent with the opinions expressed in yesterday's FDA Advisory Committee meeting, all of these end-points should be considered in the evaluation and ultimate approval of immunotherapeutics.
Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to human health. It operates in the following major therapeutic areas: cardiovascular, bone metabolism/rheumatology, gastroenterology, central nervous system and analgesia, anti-infectives, AIDS, cancer, hypersensitivity, and plasma derivatives. RPR has annualized sales of more than $3.6 billion and an annualized investment in research of over $440 million. The company operates in all major markets of the world.
/CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/ CO: Rhone-Poulenc Rorer Inc. ST: Pennsylvania IN: MTC SU: CC-JS -- PH017 -- 3904 11/13/91 11:35 EST